CytRx Corp. will supply its patented adjuvant for testing ofmalaria vaccines in a cooperative research effort sponsored bythe Centers for Disease Control, the company said Thursday.

The Norcross, Ga., company (NASDAQ:CYTR) did not disclosewhich vaccines will be tested or when the tests will start.

Adjuvants work with vaccines to boost the body's immuneresponse. The CytRx adjuvant is a copolymer of ethylene oxideand propylene oxide.

Ribi ImmunoChem Research Inc. (NASDAQ:RIBI) of Hamilton,Mont., has an adjuvant in Phase II testing with a malariavaccine made by SmithKline Beecham. Ribi's compound includesmonophosphoryl lipid A, a derivative of the bacterial toxin thatprompts the immune system's overreaction in septic shock.

(c) 1997 American Health Consultants. All rights reserved.